Preliminary Results 2020

LEI No. 213800QIPVTK5ES5UU36

23 June 2019

Scapa Group Ltd
Preliminary Results

Scapa Group Ltd (AIM: SCPA), the diversified Healthcare and Industrial company focused on bringing best-in-class innovation, design and manufacturing solutions to its customers, today announces its preliminary results for the 12 months ended 31 March 2020.

Group Financial Highlights:
• Group revenue increased 2.8% to £320.6m (2019: £311.8m)
• Trading profit1 down 27.2% to £27.8m (2019: £38.2m) following the loss of the ConvaTec contract
• Group operating loss of £47.3m following exceptional items of £68.4m including impairments of £54.6m, site closure costs of £8.0m and contract-specific exceptional costs of £7.2m associated with the loss of the ConvaTec contract
• EBITDA2 down 13.5% to £39.7m (2019: £45.9m)
• Adjusted earnings per share3 decreased 34.4% to 12.4p (2019: 18.9p); basic loss per share 31.9p (2019: earningsof 5.3p)
• Adjusted net debt4 of £54.4m (2019: £43.7m)

Divisional Highlights 

• Revenue increased 7.6% to £152.0m (2019: £141.3m); 4.5% on a constant currency basis5, despite the loss of the ConvaTec contract
• On a continuing basis6, revenue increased 5.1% to £144.7m (2019: £137.7m); 2.0% on a constant currency basis5
• Trading profit1 of £13.7m (2019: £20.9m) is 34.4% lower, largely due to the loss of the ConvaTec contract and a weaker performance at our BioMed site in Dallas, which was impacted by higher one-off costs following major investments in capacity and systems including consultant and subsequent validation costs. On a continuing basis6 trading profit was £6.4m (2019: £17.3m)
• Continued focus on operational efficiencies through the consolidation of four separate sites into the centres of excellence in Gargrave, UK, and Knoxville, US
• Leveraged manufacturing, technology and development expertise to deliver over 100 programmes in the development pipeline delivering £11.7m in FY20
• Completed two new technology transfers with existing leading consumer healthcare customers

• Revenue of £168.6m (2019: £170.5m) was 1.1% lower due to adverse macro conditions; 1.9% lower on a constant currency basis5
• Trading profit1 of £19.5m (2019: £22.3m), with trading profit margin reducing to 11.6% (2019: 13.1%) due to product mix
• 10% revenue growth in Asia made up shortfalls in Europe and North America across the Consumer portfolio
• Delivered 5.5% revenue growth in Cable segment driven by Europe
• Delivered 2.8% revenue growth in European Automotive segment and achieved 5% revenue growth in North American Construction segment, despite overall slowdown across these markets
• Specialty segment declined in revenue due to product rationalisation and reduction in volume at key accounts
• Invested in new coating line and distribution facility in India to support growth and migration to more value added businesses

COVID-19 Update and Outlook:
• Successful completion of a placing and subscription of new ordinary shares to raise gross proceeds of £32.6m, together with the Board proposing a suspension of the dividend this year to further strengthen the Balance Sheet
• Secured a new £15m short-term facility to sit alongside the Group's existing £80m revolving credit facility and for certain temporary revisions to its existing covenant arrangements
• Pro forma net debt7 following the placing of £22.9m which is 0.58x 2020 EBITDA
• Continue to execute a well-developed COVID-19 action plan focused on cost efficiencies, managing cash and preserving liquidity
• Received a US government grant of US$5m under the Paycheck Protection Program
• Year-to-date trading better than initially forecast under Scapa’s COVID-19 scenario, but recovery is at a slower pace
• Continue to execute against the COVID-19 scenario and expect trading to be in line with the outlook provided at the time of the placing
• Appointed Chris Brinsmead as Non-Executive Chairman to succeed Larry Pentz, who will step down after three years as Chairman at the Company's AGM on 7 August 2020. Chris's appointment will be effective from 7 August 2020 (see separate announcement)
• Scapa would like to recognise its employees who have gone above and beyond during the global pandemic. The Group has managed to maintain full production at all of its European and North American sites. Their dedication nd commitment to supporting Scapa's customers during these unprecedented times is greatly appreciated

For full press release and presentation see Results and Presentations

Commenting on the results Chief Executive, Heejae Chae, said:
"I am pleased to report a resilient financial and operational performance during the year, despite the significant impact of the loss of the ConvaTec contract. We have delivered record revenue and made good progress on our operational footprint plans for integrating and streamlining the business. In Healthcare, we continue to focus on operational efficiencies to optimise assets, enhance capabilities and develop a strong pipeline. In Industrial, despite substantial market contraction in our key market segments, especially in the second half of the year, we delivered a trading profit margin in the top tier of overall performance by our peers. “As we navigate through the COVID-19 pandemic, it is difficult to predict how long the restrictions will last or the shape of the recovery. Regardless of the ‘new normal’, our strategy is to position ourselves to react decisively and quickly to take advantage of the opportunities that will emerge. To provide flexibility to fully realise these opportunities, in May 2020 we strengthened our Balance Sheet through a successful placing and subscription, as well as a debt-refinancing to provide additional liquidity. Whilst we recognise the past year has been difficult, we are confident these actions, alongside cost saving initiatives, will enable Scapa to cement its strong market position, trusted outsource partner status and ability to quickly support its customers as we continue to focus on rigorous execution of our strategy in the short, medium and long-term."

1 Trading profit – profit before exceptional items, acquisition costs, amortisation of intangible assets and legacy pensions costs
2 EBITDA – Trading profit before depreciation
3 Adjusted earnings per share is calculated by dividing the trading profit less interest on cash borrowings, less tax on operating activities by the weighted number of ordinary shares in issue during the year
4 Adjusted net debt – Cash and cash equivalents net of borrowings including restricted cash and unamortised debt issue costs adjusted to exclude lease liabilities
5 Constant currency basis – prior year results translated at current year’s average exchange rates
6 Continuing basis – Group results before the impact of IFRS 15 provision release for the Systagenix acquisition
7 Adjusted net debt plus net proceeds from equity placement

For further information:
Scapa Group Ltd Heejae Chae – Group Chief Executive
Oskar Zahn – Chief Financial Officer 
Tel: 0161 301 7430

Numis Securities Limited (Nominated Adviser/Joint Broker) 
Mark Lander, Freddie Barnfield 
Tel: 020 7260 1000

Berenberg (Joint Broker)
Chris Bowman, Toby Flaux 
Tel: 020 3207 7800

FTI Consulting (Media Relations) 
Simon Conway, Victoria Foster Mitchell 
Tel: 020 3727 1000

About Scapa Group Ltd 
Scapa Group Ltd is a diversified Healthcare and Industrial company focused on bringing best-in-class innovation, design and manufacturing solutions to its customers.

Scapa Healthcare is the trusted strategic partner of choice for the world’s leading companies in Advanced Wound Care, Consumer Wellness and Medical Device Fixation. We partner with the top global MedTech companies to develop and manufacture innovative skin friendly medical device fixation and topical solutions, from inception through to market delivery, from our state-of-the-art facilities. 
For further information, please visit

Scapa Industrial is a global supplier of bonding solutions and manufacturer of adhesive-based products which offer meaningful value in industrial applications due to their lightweight, easy-to-apply properties. We are recognised for our unparalleled range of products, including adhesive tapes, films and foams, and we can engineer custom designs for even the most unique applications.
For further information, please visit

For full press release and presentation see Results and Presentations